True. Aromatase inhibitors (AIs), such as anastrozole, letrozole, and exemestane, are a cornerstone of treatment for hormone receptor-positive (estrogen-responsive) breast cancer in postmenopausal women. They work on the principle of endocrine disruption for therapeutic benefit. Aromatase is the enzyme responsible for the final step in estrogen synthesis, converting androgens (like androstenedione) into estrogens (estrone and estradiol). In postmenopausal women, the primary source of estrogen is this peripheral conversion in fat, muscle, and breast tissue. Aromatase inhibitors bind to and inhibit the aromatase enzyme, dramatically reducing the production of estrogen throughout the body. By depriving estrogen-dependent breast cancer cells of their growth signal, these drugs can slow or stop cancer progression and reduce the risk of recurrence.

Break down complex topics into smaller, manageable chunks for easier recall.

Zambia

• Joseph Soko – 101 pts

• Visual Pathway Lesions
• Positive and Negative Symptoms
• Hallucinations and Delusions
• Antipsychotic Medications
• Emergency: Environmental Emergencies